Literature DB >> 19002423

[Are there therapeutic approaches of non-alcoholic fatty liver disease and its complications?].

S Strahl1, K P Maier.   

Abstract

As little as 10 years ago, there was scepticism as to weather non-alcoholic fatty liver disease is a clinical condition. With the increasing prevalence of obesity, diabetes mellitus and the metabolic syndrome in the general population, non-alcoholic fatty liver disease has become a household diagnosis in clinical practice of several medical specialities. Meanwhile, it is the primary cause for elevated liver enzymes of unknown cause in clinical practice. Treatment is focused on the improvement of insulin resistance and of antioxidative mechanisms, mainly by life-style modifications including weight loss and exercise. Drug therapy cannot be recommended at this time, because studies showing positive effects on morbidity and mortality are still lacking. In addition, issues concerning long term safety and side effects of drugs still have to be resolved.

Entities:  

Mesh:

Year:  2008        PMID: 19002423     DOI: 10.1007/s00108-008-2151-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  34 in total

1.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

Authors:  Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

2.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

Authors:  T Ueno; H Sugawara; K Sujaku; O Hashimoto; R Tsuji; S Tamaki; T Torimura; S Inuzuka; M Sata; K Tanikawa
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

Review 3.  Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance.

Authors:  Herbert Tilg; Gökhan S Hotamisligil
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

4.  Interindividual variation in posture allocation: possible role in human obesity.

Authors:  James A Levine; Lorraine M Lanningham-Foster; Shelly K McCrady; Alisa C Krizan; Leslie R Olson; Paul H Kane; Michael D Jensen; Matthew M Clark
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

5.  Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance.

Authors:  D A de Luis; R Aller; O Izaola; M Gonzalez Sagrado; R Conde; J M Gonzalez
Journal:  Diabetes Res Clin Pract       Date:  2007-09-04       Impact factor: 5.602

6.  Dietary fat content modifies liver fat in overweight nondiabetic subjects.

Authors:  Jukka Westerbacka; Katriina Lammi; Anna-Maija Häkkinen; Aila Rissanen; Irma Salminen; Antti Aro; Hannele Yki-Järvinen
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

7.  A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

Authors:  Leon A Adams; Claudia O Zein; Paul Angulo; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

Review 8.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Authors:  Robin Christensen; Pernelle Kruse Kristensen; Else Marie Bartels; Henning Bliddal; Arne Astrup
Journal:  Lancet       Date:  2007-11-17       Impact factor: 79.321

9.  Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study.

Authors:  Shira Zelber-Sagi; Dorit Nitzan-Kaluski; Rebecca Goldsmith; Muriel Webb; Laurie Blendis; Zamir Halpern; Ran Oren
Journal:  J Hepatol       Date:  2007-08-14       Impact factor: 25.083

10.  Use of thiazolidinediones and fracture risk.

Authors:  Christian Meier; Marius E Kraenzlin; Michael Bodmer; Susan S Jick; Hershel Jick; Christoph R Meier
Journal:  Arch Intern Med       Date:  2008-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.